BETHESDA, Md., March 7, 2014 /PRNewswire/ -- Northwest
Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company
developing DCVax® personalized immune therapies for solid tumor
cancers, announced today, in response to shareholder inquiries,
that the Data Safety Monitoring Board (DSMB) has made an unblinded
review of the safety data for the Company's ongoing international
Phase III GBM Trial, and has recommended that the trial continue as
planned.
The DSMB's review of the efficacy data is still pending.
Dr. Marnix Bosch, Chief Technical
Officer of NW Bio noted, "We are pleased with the recommendation of
the DSMB to continue the trial as planned. This is an
important step in the ongoing progress of our Phase III trial."
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on
developing immunotherapy products to treat cancers more effectively
than current treatments, without toxicities of the kind associated
with chemotherapies, and on a cost-effective basis, in both
the United States and
Europe. The Company has a broad platform technology for DCVax
dendritic cell-based vaccines. The Company's lead program is
a 312-patient Phase III trial in newly diagnosed Glioblastoma
multiforme (GBM). GBM is the most aggressive and lethal form
of brain cancer. The Company is under way with a 60-patient
Phase I/II trial with DCVax-Direct for all inoperable solid tumors
cancers, with a primary efficacy endpoint of tumor regression.
The Company previously received clearance from the FDA for a
612-patient Phase III trial in prostate cancer. The Company
also conducted a Phase I/II trial with DCVax for metastatic
ovarian cancer together with the University of
Pennsylvania.
Disclaimer
Statements made in this news release that are not historical
facts, including statements concerning future treatment of patients
using DCVax and future clinical trials, are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "expect," "believe,"
"intend," "design," "plan," "continue," "may," "will,"
"anticipate," and similar expressions are intended to identify
forward-looking statements. Actual results may differ
materially from those projected in any forward-looking
statement. Specifically, there are a number of important
factors that could cause actual results to differ materially from
those anticipated, such as risks related to the Company's ability
to raise additional capital, risks related to the Company's ability
to enroll patients in its clinical trials and complete the trials
on a timely basis, uncertainties about the clinical trials process,
uncertainties about the timely performance of third parties, and
whether the Company's products will demonstrate safety and
efficacy, and risks related to the Company's and Cognate's
abilities to carry out the intended manufacturing expansions
contemplated in the Cognate Agreements. Additional information on
these and other factors, including Risk Factors, which could affect
the Company's results, is included in its Securities and Exchange
Commission ("SEC") filings. Finally, there may be other
factors not mentioned above or included in the Company's SEC
filings that may cause actual results to differ materially from
those projected in any forward-looking statement. You should
not place undue reliance on any forward-looking statements.
The Company assumes no obligation to update any forward-looking
statements as a result of new information, future events or
developments, except as required by securities laws.
Logo -
http://photos.prnewswire.com/prnh/20110329/SF73084LOGO
SOURCE Northwest Biotherapeutics, Inc.